Back in early 2012, a number of physicians around the U.S. began fielding some unusual requests from Alzheimer's patients for a prescription covering Targretin (bexarotene), a cancer drug sold by Eisai.
The German biotech Evotec and Johnson & Johnson have the inside track on drug development based on a Harvard lab's discovery of a hormone that spurs replication of insulin-producing beta cells. The finding opens the door to a novel mechanism for treating diabetes, yet researchers caution that the impressive data in mice have some time to go before they are replicated in humans.
The NEJM 's recent publication of the first randomized, controlled trial of fecal transplantation (FT) is a big deal for research of the human microbiome, which is the community of microbes that colonize the body and impact infection, immune reactions and other aspects of our health. I can't think of a better response to the warnings of hype for this new field of research than convincing clinical data validating microbiome modulation as a therapeutic approach. More >>
Theravance announced Thursday afternoon that it plans to break apart into two publicly traded companies: a company dubbed Royalty Management that will take over Theravance's late-stage respiratory drugs and another called Theravance Biopharma focused on small-molecule R&D.
The big biotech reported in its quarterly statement that the agency has provided the coveted "breakthrough" status for a combination of daclatasvir with two other direct-acting antivirals, asunaprevir, an NS3 protease inhibitor and BMS-791325, an NS5B non-nucleoside polymerase inhibitor.
The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, says that F2 Biosciences III stepped up to lead the latest round of $43 million.
With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent claim by Johnson & Johnson, one of its chief rivals in the risky game of Alzheimer's drug development.
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
Antibiotics maker Achaogen announced today that it has landed a $60 million contract option from the federal Biomedical Advanced Research and Development Authority to further the development of its drug plazomicin to treat patients with serious Gram-negative bacterial infections.
The designation was based on Phase Ib data that showed significant early signs of antitumor activity in some patients with aggressive cases of the deadly skin cancer.